IND Exemptions For Cancer Trials To Be Based On Risk, Not Just Size
FDA has revised its guidance on IND exemptions for marketed cancer drugs to allow some large randomized trials to qualify
You may also be interested in...
FDA is seeking to reduce the number of unnecessary IND submissions it receives by issuing a draft guidance clarifying IND exemptions for oncologic products
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials